

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED

精優藥業控股有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 00858)

VOLUNTARY ANNOUNCEMENT

PROGRESS OF CLINICAL TRIAL ON ORAL INSULIN ENTERIC-COATED SOFT CAPSULES

This is a voluntary announcement made by Extrawell Pharmaceutical Holdings Limited (the “Company”, together with its subsidiaries, the “Group”).

The board (the “Board”) of directors of the Company is pleased to announce that, in accordance with the Phase III clinical trial protocol (the “Protocol”) filed with the State Food and Drug Administration of the People’s Republic of China (the “PRC”), the Group has recently completed part A of the Protocol relating to the multi-centered, randomized, double-blinded and placebo-controlled clinical trial of its oral insulin enteric-coated soft capsules (the “Medicine”) on treatment of Type 2 diabetes. With reference to the benchmark indicators, in particular, on the effect of reducing blood glucose level in diabetics through absorption of the Medicine into blood circulation of human body, the statistical outcome of the per-protocol set (PPS) analysis shows that the bio-efficacy of the Medicine in the treatment group (where patients were given the Medicine) was significantly superior to that of the control group (where patients were given placebo).

The Protocol designed by recognised clinical trial bases and led by the Peking University People’s Hospital in the PRC consists of two parts. As part A of the Protocol has already been completed with satisfactory results, in order to further validate the efficacy of the use of the Medicine in more diabetic testees, the Group is working with the project team and clinical experts of the Peking University People’s Hospital in the PRC to conduct part B of the clinical trial on the Medicine contemplated in the Protocol, among others, in larger scale of participating cases. It is expected that such extended clinical trial will commence in due course.

Further announcements regarding the progress of the clinical trial of the Medicine will be made as and when appropriate. Shareholders and public investors should exercise caution when dealing in the shares of the Company.

By order of the Board
Extrawell Pharmaceutical Holdings Limited
Xie Yi
Director

Hong Kong, 25 February 2013

As at the date of this announcement, the executive directors are Dr. Mao Yumin, Dr. Xie Yi, Dr. Lou Yi and Ms. Wong Sau Kuen and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.

** For identification purpose only*